DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide) is a 9-amino acid neuropeptide (WAGGDASGE; CAS 62568-57-4; MW 849.9 g/mol) first isolated from the cerebral venous blood of sleeping rabbits. It is associated with the promotion of EEG delta wave activity and circadian rhythm normalization, and has been incorporated into the Khavinson longevity protocol alongside Epithalon and Thymalin in investigations of healthy aging. Preclinical studies have also explored its potential roles in growth hormone release, luteinizing hormone regulation, antioxidant activity, and adaptive responses to physiological stress.

This naturally occurring neuropeptide appears to influence multiple biological pathways involved in sleep-wake regulation, neuroendocrine signaling, and stress adaptation. Unlike compounds that induce sedation through direct GABAergic activity, DSIP has been investigated for its ability to support the physiological processes associated with delta wave sleep, the deepest stage of non-rapid eye movement sleep linked to restoration and recovery.

In research settings, DSIP has demonstrated the ability to modulate neurotransmitter systems involving GABA, glutamate, and monoamines while influencing hypothalamic-pituitary axis activity. Experimental findings suggest effects on nocturnal growth hormone release, luteinizing hormone secretion, and antioxidant defense mechanisms that may help protect neural tissues from oxidative stress. The peptide's WAGGDASGE sequence exhibits relative enzymatic resistance, contributing to greater stability compared with many naturally occurring neuropeptides.

DSIP's inclusion within the Khavinson longevity framework reflects growing interest in the relationship between sleep quality, circadian rhythm integrity, and healthy aging. Its broad effects on sleep architecture, neuroendocrine regulation, and stress resilience make it a useful research tool for exploring the interconnected pathways linking sleep, metabolism, and longevity.